Cancer Centers Rush for New Pancreatic Cancer Drug Trial

U.S. cancer centers are racing to enroll patients in an early access program for a promising pancreatic cancer drug from Revolution Medicines while awaiting FDA approval. The drug, daraxonrasib, has shown potential to double survival rates in patients with advanced pancreatic cancer, prompting widespread interest and challenges in program implementation.

U.S. cancer centers are urgently trying to enroll patients in an early access program for a promising pancreatic cancer drug developed by Revolution Medicines. The drug, called daraxonrasib, has demonstrated the potential to double survival rates in advanced cases of the disease, which is among the deadliest forms of cancer.

The Food and Drug Administration permitted the expanded access program, allowing patients to access the treatment ahead of potential approval. Oncologists note that implementing and managing this program will demand substantial effort and resources from cancer centers, which face significant interest from patients.

CEO of Revolution Medicines, Mark Goldsmith, has refrained from providing specific timelines for FDA submission or estimating how many patients might seek access. Meanwhile, oncologists stress the need for efficient processes to handle the influx of requests, urging the FDA to establish streamlined protocols.